estrogen (e2)  (Serono)

Journal: International journal of molecular sciences

Article Title: Effects of Acrylamide on Mouse Implantation and Decidualization.

doi: 10.3390/ijms26094129

Figure Lengend Snippet: Figure 2. The concentrations of uterine E2 and P4 on days 4, 5, and 8 of pregnancy in mice treated with 0, 20 mg ACR/kg/d (20 mg ACR) and 30 mg ACR/kg/d (30 mg ACR) for 3 months, respectively. (a) The concentrations of uterine E2 on days 4, 5 and 8 of pregnancy. (b) The concentrations of uterine P4 on days 4, 5, and 8 of pregnancy. ns: no significant.

Article Snippet: Mouse E2 (CSB-E07280m, Cusabio, Wuhan, China) and P4 (E-OSEL-M0006, Elabscience, Wuhan, China) ELISA kits were used to analyze the concentration of E2 and P4 in uterine su- Int.

Techniques:

Journal: Cells

Article Title: Proof-of-Concept for Long-Term Human Endometrial Epithelial Organoids in Modeling Menstrual Cycle Responses

doi: 10.3390/cells13211811

Figure Lengend Snippet: Human endometrium organoids respond to estrogen treatment: ( A ) treatment plan and violin plots of gene expression changes in hEOs during 28 days with estrogen (E2) treatment measured by quantitative polymerase chain reaction (qPCR); ( B ) representative immunofluorescent images showing, Ki67, PGR (PR), E-cadherin (E-Cad), and PAEP expression through 28-day estrogen treatment in hEOs from donor 1 (cyan), donor 2 (red), and donor 3 (green). Results illustrated in ( A ) represent mean ± SD from three independent biological replicates ( n = 3 donors), each with three experimental replicates ( n = 9 total) and analyzed by one-way ANOVA with Tukey’s multiple-comparison test and post hoc correction, * p < 0.05, ** p < 0.01, and *** p < 0.001; scale bar in ( B ): 50 µm.

Article Snippet: hEOs were divided into subgroups according to the hormone treatment regimen presented in C. Doses of hormones used were as follows: 0.1 nM (day 0–7), 1 nM (day 7–21) and 0.1 nM (day 21–28) for estrogen (E2) (Merck, Darmstadt, Germany); 10 nM (day 14–21) and 50 nM (day 21–28) for progesterone (P4) (Merck, Darmstadt, Germany); and 0.5 mM dibutyryl cyclic adenosine monophosphate (AMP) (dbcAMP, day 14–21 and day 21–28) (MedChemExpress, South Brunswick, NJ, USA).

Techniques: Gene Expression, Real-time Polymerase Chain Reaction, Expressing, Comparison

Journal: Cells

Article Title: Proof-of-Concept for Long-Term Human Endometrial Epithelial Organoids in Modeling Menstrual Cycle Responses

doi: 10.3390/cells13211811

Figure Lengend Snippet: Sequential estrogen and progesterone treatment mimics the secretory phase in human endometrial organoids: ( A ) treatment plan and violin plots of gene expression changes in hEOs during 28 days with sequential progesterone (P4) treatment following estrogen (E2) day 14 onwards, measured by quantitative polymerase chain reaction (qPCR); ( B ) representative immunofluorescent images showing ESR1 (ER), PGR (PR), and PAEP expression through 28-day treatment in hEOs from donor 1 (cyan), donor 2 (red), and donor 3 (green). Results illustrated in ( A ) represent mean ± SD from three independent biological replicates ( n = 3 donors), each with three experimental replicates ( n = 9 total), and analyzed by one-way ANOVA with Tukey’s multiple-comparison test and post hoc correction, * p < 0.05, ** p < 0.01, and *** p < 0.001; scale bar in ( B ): 50 µm.

Article Snippet: hEOs were divided into subgroups according to the hormone treatment regimen presented in C. Doses of hormones used were as follows: 0.1 nM (day 0–7), 1 nM (day 7–21) and 0.1 nM (day 21–28) for estrogen (E2) (Merck, Darmstadt, Germany); 10 nM (day 14–21) and 50 nM (day 21–28) for progesterone (P4) (Merck, Darmstadt, Germany); and 0.5 mM dibutyryl cyclic adenosine monophosphate (AMP) (dbcAMP, day 14–21 and day 21–28) (MedChemExpress, South Brunswick, NJ, USA).

Techniques: Gene Expression, Real-time Polymerase Chain Reaction, Expressing, Comparison

Journal: Cells

Article Title: Proof-of-Concept for Long-Term Human Endometrial Epithelial Organoids in Modeling Menstrual Cycle Responses

doi: 10.3390/cells13211811

Figure Lengend Snippet: cAMP enhances progesterone-induced differentiation of human endometrial organoids: ( A ) treatment plan and violin plots of gene expression changes in hEOs during 28 days with sequential progesterone (P4) and cAMP treatment following estrogen (E2) treatment from day 14 onwards in hEOs measured by quantitative polymerase chain reaction (qPCR); ( B ) representative immunofluorescent images showing ESR1 (ER), PGR (PR), and PAEP expression at day 21 and 28 through 28-day treatment in hEOs from donor 1 (cyan), donor 2 (red), and donor 3 (green). Results illustrated in ( A ) represent mean ± SD from three independent biological replicates ( n = 3 donors), each with three experimental replicates ( n = 9 total), and analyzed by one-way ANOVA with Tukey’s multiple-comparison test and post hoc correction, * p < 0.05, ** p < 0.01, and *** p < 0.001; scale bar in ( B ): 50 µm.

Article Snippet: hEOs were divided into subgroups according to the hormone treatment regimen presented in C. Doses of hormones used were as follows: 0.1 nM (day 0–7), 1 nM (day 7–21) and 0.1 nM (day 21–28) for estrogen (E2) (Merck, Darmstadt, Germany); 10 nM (day 14–21) and 50 nM (day 21–28) for progesterone (P4) (Merck, Darmstadt, Germany); and 0.5 mM dibutyryl cyclic adenosine monophosphate (AMP) (dbcAMP, day 14–21 and day 21–28) (MedChemExpress, South Brunswick, NJ, USA).

Techniques: Gene Expression, Real-time Polymerase Chain Reaction, Expressing, Comparison